This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Sep;9(9):e599-e600.

doi: 10.1016/S2352-3018(22)00172-2. Epub 2022 Jul 19.

Dolutegravir for children with HIV-associated tuberculosis

Tammy Meyers¹, Paul Krogstad²

Affiliations

Affiliations

¹ Department of Paediatrics and Child Health, School of Medicine, University of the Witwatersrand, Johannesburg, South Africa; Discipline of Paediatrics and Child Health, School of Clinical Medicine, University of New South Wales, Sydney, NSW 2052, Australia. Electronic address: tammy_meyers.morris@unsw.edu.au.
² Department of Pediatrics and Department of Molecular and Medical Pharmacology, Division of Pediatric Infectious Diseases, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, US.

PMID: 35868340
DOI: 10.1016/S2352-3018(22)00172-2

Comment

Dolutegravir for children with HIV-associated tuberculosis

Tammy Meyers et al. Lancet HIV. 2022 Sep.

. 2022 Sep;9(9):e599-e600.

doi: 10.1016/S2352-3018(22)00172-2. Epub 2022 Jul 19.

Authors

Tammy Meyers¹, Paul Krogstad²

Affiliations

¹ Department of Paediatrics and Child Health, School of Medicine, University of the Witwatersrand, Johannesburg, South Africa; Discipline of Paediatrics and Child Health, School of Clinical Medicine, University of New South Wales, Sydney, NSW 2052, Australia. Electronic address: tammy_meyers.morris@unsw.edu.au.
² Department of Pediatrics and Department of Molecular and Medical Pharmacology, Division of Pediatric Infectious Diseases, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, US.

PMID: 35868340
DOI: 10.1016/S2352-3018(22)00172-2

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment on

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Turkova A, Waalewijn H, Chan MK, Bollen PDJ, Bwakura-Dangarembizi MF, Kekitiinwa AR, Cotton MF, Lugemwa A, Variava E, Ahimbisibwe GM, Srirompotong U, Mumbiro V, Amuge P, Zuidewind P, Ali S, Kityo CM, Archary M, Ferrand RA, Violari A, Gibb DM, Burger DM, Ford D, Colbers A; ODYSSEY Trial Team. Turkova A, et al. Lancet HIV. 2022 Sep;9(9):e627-e637. doi: 10.1016/S2352-3018(22)00160-6. Epub 2022 Jul 19. Lancet HIV. 2022. PMID: 35868341 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information